Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 2.16B |
| Revenue (ttm) | 276.98M |
| Net Income (ttm) | -59.50M |
| Shares Out | 153.98M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 730,433 |
| Open | 14.21 |
| Previous Close | 14.21 |
| Day's Range | 13.71 - 14.30 |
| 52-Week Range | 7.16 - 20.76 |
| Beta | 2.30 |
| Analysts | Strong Buy |
| Price Target | 17.78 (+26.82%) |
| Earnings Date | May 5, 2026 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima... [Read more]
Financial Performance
In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ADPT stock is "Strong Buy." The 12-month stock price target is $17.78, which is an increase of 26.82% from the latest price.
News
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotechnologies Transcript: TD Cowen 46th Annual Health Care Conference
Strong volume growth, guideline inclusions, and pricing improvements are driving double-digit expansion, with EMR integration and clinical data supporting further adoption. International expansion is capital-efficient, and the technology remains the gold standard in MRD, with robust financial margins and a promising immune medicine pipeline.
Adaptive Biotechnologies Earnings Call Transcript: Q4 2025
Achieved 55% revenue growth and 68% lower cash burn in 2025, with MRD profitability and strong clonoSEQ test volume growth. 2026 guidance targets 22% MRD revenue growth, over 30% test volume increase, and positive company-wide adjusted EBITDA and free cash flow by year-end.
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
MRD testing volumes and revenues continue to grow, driven by blood-based testing, community expansion, and updated clinical guidelines. ASPs are rising, with a clear path to $1,700–$1,800 by 2029, and the company expects positive adjusted EBITDA and free cash flow in 2026. Immune medicine is advancing through data partnerships and predictive modeling.
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech
Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A inve...
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research ...
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock is trading lower on Friday, despite no company-specific news, likely reacting to Natera Inc.'s (NASDAQ: NTRA) acquisition of cancer diagnostic...
Adaptive Biotechnologies Transcript: Piper Sandler 37th Annual Healthcare Conference
Gross margins improved by 2% in Q3, with a 5%-8% lift expected over the next year. EMR integration and blood-based testing are driving growth, supported by expanded reimbursement and new clinical guidelines. Key catalysts include further data generation, margin gains, and major clinical trial readouts.
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies Transcript: Jefferies London Healthcare Conference 2025
Strong quarterly growth in volumes, ASP, and gross margin was supported by expanded payer coverage, EMR integration, and robust data generation. Pharma backlog exceeds $200 million, with a shift toward primary endpoints, and R&D investments in AI and autoimmunity are advancing, all while maintaining profitability.
Adaptive Biotechnologies Earnings Call Transcript: Q3 2025
Q3 saw robust MRD revenue growth, margin expansion, and positive cash flow, driven by clinical adoption, EMR integration, and payer wins. Full-year MRD guidance was raised, with strong volume and ASP momentum, while regulatory and competitive positioning remain favorable.
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Achieved key operational and financial milestones ahead of schedule, including EBITDA profitability and major EMR integrations. Community market penetration and blood-based testing are driving rapid growth, while clinical utility data and new guidelines support increased adoption. ASP and margin improvements, along with strategic partnerships, position the business for strong future performance.
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies Earnings Call Transcript: Q2 2025
Q2 saw 36% revenue growth, MRD business profitability, and raised full-year guidance. EMR integrations and updated guidelines are driving volume and pricing gains, with strong momentum in both clinical and pharma MRD segments.
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...